DE69920681D1 - Humaner k+ ionenkanal und therapeutische verwendungen davon - Google Patents

Humaner k+ ionenkanal und therapeutische verwendungen davon

Info

Publication number
DE69920681D1
DE69920681D1 DE69920681T DE69920681T DE69920681D1 DE 69920681 D1 DE69920681 D1 DE 69920681D1 DE 69920681 T DE69920681 T DE 69920681T DE 69920681 T DE69920681 T DE 69920681T DE 69920681 D1 DE69920681 D1 DE 69920681D1
Authority
DE
Germany
Prior art keywords
nucleic acid
methods
ion channel
present
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69920681T
Other languages
English (en)
Other versions
DE69920681T2 (de
Inventor
Luis Angel Pardo-Fernandez
Walter Stuehmer
Synnoeve Beckh
Andrea Brueggemann
Camino Fernandez-Miranda D Del
Perez Araceli Sanchez
Ruediger Weseloh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of DE69920681D1 publication Critical patent/DE69920681D1/de
Application granted granted Critical
Publication of DE69920681T2 publication Critical patent/DE69920681T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69920681T 1998-04-21 1999-04-21 Humaner k+ ionenkanal und therapeutische verwendungen davon Expired - Lifetime DE69920681T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98107268 1998-04-21
EP98107268 1998-04-21
PCT/EP1999/002695 WO1999054463A2 (en) 1998-04-21 1999-04-21 Human k+ ion channel and therapeutic applications thereof

Publications (2)

Publication Number Publication Date
DE69920681D1 true DE69920681D1 (de) 2004-11-04
DE69920681T2 DE69920681T2 (de) 2005-09-08

Family

ID=8231794

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920681T Expired - Lifetime DE69920681T2 (de) 1998-04-21 1999-04-21 Humaner k+ ionenkanal und therapeutische verwendungen davon

Country Status (10)

Country Link
US (7) US6638736B1 (de)
EP (1) EP1073738B1 (de)
JP (2) JP2002512029A (de)
AT (1) ATE278017T1 (de)
CA (1) CA2323571A1 (de)
DE (1) DE69920681T2 (de)
DK (1) DK1073738T3 (de)
ES (1) ES2230852T3 (de)
PT (1) PT1073738E (de)
WO (1) WO1999054463A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323571A1 (en) * 1998-04-21 1999-10-28 Luis Angel Pardo-Fernandez Novel human k+ ion channel and therapeutic applications thereof
DE10025620A1 (de) * 2000-05-24 2001-12-06 Forschungsgesellschaft Genion Verfahren zur Herstellung von Chimären zwischen bakteriellen und eukaryotischen Kaliumkanälen auf festen Trägern und deren Verwendung zur Identifizierung von Kaliumkanalagonisten und -antagonisten
DE10224534A1 (de) * 2002-05-31 2003-12-11 Juergen Dolderer Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung
JP2008520186A (ja) * 2004-10-01 2008-06-19 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
WO2006037611A2 (en) * 2004-10-01 2006-04-13 Centro De Investigación Y De Estudios Avanzados Del Ipn Methods for the early diagnosis of viral infections, inflammatory diseases, a predisposition for proliferative disorders or hyperplasia by analysing eag or erg expression levels
AU2013201604B2 (en) * 2007-04-13 2014-08-14 Southern Research Institute Anti-angiogenic agents and methods of use
ES2334084B1 (es) * 2007-12-21 2011-01-24 Inst Cientifico Tecnol Navarra Marcadores geneticos para el pronostico de la esclerosis multiple.
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
TWI570415B (zh) * 2015-10-02 2017-02-11 A spring probe having an outer sleeve and a probe device having the spring probe
EP3195727A1 (de) 2016-01-22 2017-07-26 Forschungsinstitut Fur Biologischen Landbau (FiBL) Duddingtonia flagrans-stamm und futterzusatzformulierung zur biologischen schädlingsbekämpfung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB9303210D0 (en) 1993-02-17 1993-03-31 Univ Manitoba Cancer treatment
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
AU3440697A (en) * 1996-07-02 1998-01-21 Novartis Consumer Health S.A. Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
US6610827B1 (en) * 1997-10-29 2003-08-26 Elan Pharmaceuticals, Inc. Potassium channel subunit polypeptide and polynucleotide compositions and uses therefor
CA2323571A1 (en) * 1998-04-21 1999-10-28 Luis Angel Pardo-Fernandez Novel human k+ ion channel and therapeutic applications thereof

Also Published As

Publication number Publication date
EP1073738B1 (de) 2004-09-29
CA2323571A1 (en) 1999-10-28
JP2009235091A (ja) 2009-10-15
DE69920681T2 (de) 2005-09-08
US20030087377A1 (en) 2003-05-08
US20030087378A1 (en) 2003-05-08
US20100021467A1 (en) 2010-01-28
DK1073738T3 (da) 2005-01-24
US20030092120A1 (en) 2003-05-15
ATE278017T1 (de) 2004-10-15
US7314914B2 (en) 2008-01-01
PT1073738E (pt) 2005-01-31
US20080020406A1 (en) 2008-01-24
US7364845B2 (en) 2008-04-29
WO1999054463A3 (en) 2000-04-20
ES2230852T3 (es) 2005-05-01
JP2002512029A (ja) 2002-04-23
WO1999054463A2 (en) 1999-10-28
US7129207B2 (en) 2006-10-31
EP1073738A2 (de) 2001-02-07
US6638736B1 (en) 2003-10-28
US7364730B2 (en) 2008-04-29
US20030077735A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
Yin et al. Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling
Ruocco et al. A transforming growth factor-β antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury
Namyen et al. Protective effects of melatonin on methamphetamine-induced blood–brain barrier dysfunction in rat model
Lv et al. Scutellarin inhibits hypoxia‐induced epithelial‐mesenchymal transition in bladder cancer cells
BR0312913A (pt) Ativo de biciclo-pirazóis como inibidores de cinase, processo para sua preparação e composições farmacêuticas compreendendo o mesmo
Ahmed et al. Combinatory Effects of Bone Marrow‐Derived Mesenchymal Stem Cells and Indomethacin on Adjuvant‐Induced Arthritis in Wistar Rats: Roles of IL‐1β, IL‐4, Nrf‐2, and Oxidative Stress
Shou et al. Type I interferons exert anti-tumor effect via reversing immunosuppression mediated by mesenchymal stromal cells
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
Pozzi et al. MCP-1/CCR2 axis inhibition sensitizes the brain microenvironment against melanoma brain metastasis progression
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
Carvalho et al. Chemosensitization by erythropoietin through inhibition of the NF-κB rescue pathway
DE60028970D1 (de) An her2 bindende peptidverbindungen
RU2768186C2 (ru) Комбинированные лекарственные средства, содержащие модуляторы pkm2 и hmgb1
Hou et al. The inhibitory effect of IFN-γ on protease HTRA1 expression in rheumatoid arthritis
Heo et al. Radiation-induced matrix metalloproteinases limit natural killer cell-mediated anticancer immunity in NCI-H23 lung cancer cells
ATE278017T1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
Oh et al. Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
Mauceri et al. Nasally delivered VEGFD mimetics mitigate stroke-induced dendrite loss and brain damage
Welk et al. Proteasome activator PA200 regulates myofibroblast differentiation
BRPI0407544A (pt) derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
Gelati et al. Methylprednisolone acts on peripheral blood mononuclear cells and endothelium in inhibiting migration phenomena in patients with multiple sclerosis
Malone et al. Astrocytes and the tumor microenvironment inflammatory state dictate the killing of glioblastoma cells by Smac mimetic compounds
Shortt et al. A hyaluronan-binding peptide (P15-1) reduces inflammatory and catabolic events in IL-1β-treated human articular chondrocytes
Bu et al. Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1
Wang et al. Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition